Indicaciones terapéuticas y paliativas de la radioterapia en los tumores pulmonares y torácicos

  1. Casado, D. 1
  2. Bellido, L. 1
  3. Del Barco, E. 1
  4. Cigarral, B. 1
  5. Escalera, E. 1
  6. Claros, J. 1
  7. Barrios, B. 1
  8. Figuero, L. 1
  9. Olivares, A. 1
  10. López, A. 1
  11. Terán, E. 1
  12. Cruz, J.J. 1
  1. 1 Instituto de Investigación Biomédica de Salamanca (IBSAL), Servicio de Oncología Médica, Complejo Asistencial Universitario de Salamanca (CAUSA), Salamanca, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2021

Título del ejemplar: Enfermedades oncológicas (II)Tumores torácicos. Cáncer de cabeza y cuello

Serie: 13

Número: 25

Páginas: 1409-1413

Tipo: Artículo

DOI: 10.1016/J.MED.2021.02.006 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Objetivos de desarrollo sostenible

Resumen

En pacientes con tumores pulmonares cuyo tratamiento curativo no pueda ser quirúrgico, la radioterapia tiene un papel importante. La eficacia y los efectos secundarios del tratamiento dependerán tanto de la localización del tumor como de su tamaño. Una estadificación correcta y rápida es esencial para aumentar las posibilidades de curación de estos pacientes. La radioterapia tiene su principal indicación en pacientes con tumores localizados irresecables. En función del estadio y la histología del tumor y del performans status del paciente, el modo de administrar la radioterapia variará. También puede estar indicada como tratamiento adyuvante tras una cirugía en algunos casos. Además, en los pacientes con enfermedad diseminada tiene efecto beneficioso en el control de síntomas derivados de las metástasis.

Referencias bibliográficas

  • Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vans-teenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv1-21.
  • Chi A, Liao Z, Nguyen NP, Xu J, Stea B, Komaki R. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: Clinical implications. Radiother Oncol. 2010;94(1):1-11.
  • Videtic GMM, Donington J, Giuliani M, Heinzerling J, Karas TZ, Kelsey CR, et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evi-dence-Based Guideline. Pract Radiat Oncol [Internet]. 2017 Sep 1;7(5):295-301. Disponible en: https://pub-med.ncbi.nlm.nih.gov/28596092/
  • Burdett S, Rydzewska L, Tierney J, Fisher D, Parmar MK, Arriagada R, Pignon JP, Le Pechoux C; PORT Meta‐analysis Trialists Group. Posto-perative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2016 Oct 11;10(10):CD002142.
  • Majem M, Juan O, Insa A, Reguart N, Trigo JM, Carcereny E, et al. SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). Clin Transl Oncol. 2019;21(1):3-17. doi: 10.1007/ s12094-018-1978-1.
  • van Meerbeeck JP, Kramer GWPM, Van Schil PEY, Legrand C, Smit EF, Schramel F, et al. Randomized controlled trial of resection versus ra-diotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst [Internet]. 2007 Mar 21;99(6):442-50. Disponible en: https://pubmed.ncbi.nlm.nih.gov/17374834/
  • Pless M, Stupp R, Ris HB, Stahel RA, Weder W, Thierstein S, et al. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: A phase 3 randomised trial. Lancet [Internet]. 2015 Sep 12;386(9998):1049-56. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26275735/
  • Eberhardt WEE, Pöttgen C, Gauler TC, Friedel G, Veit S, Heinrich V, et al. Phase III study of surgery versus definitive concurrent chemora-diotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non-small-cell lung cancer after induction chemotherapy and concu-rrent chemoradiotherapy (ESPATUE). J Clin Oncol [Internet]. 2015 Dec 10;33(35):4194-201. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26527789/
  • Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non - small-cell lung cancer. J Clin Oncol [Internet]. 2010 May 1;28(13):2181-90. Disponible en: https://pubmed.ncbi.nlm.nih.gov/20351327/
  • Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Prac-tice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol [Internet]. 2018 Oct 1;29 Suppl 4(Suppl 4):iv192–237. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/32169226
  • Stevens R, Macbeth F, Toy E, Coles B, Lester JF. Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer. Cochrane Database Syst Rev. 2015;1(1):CD002143. doi: 10.1002/14651858.CD002143.pub4.Disponi-ble en: https://pubmed.ncbi.nlm.nih.gov/25586198/
  • Cardona AF, Reveiz L, Ospina EG, Ospina V, Yepes A. Palliative endo-bronchial brachytherapy for non-small cell lung cancer. Cochrane Data-base Syst Rev. 2008 Apr 16;(2):CD004284. Disponible en: https://pubmed.ncbi.nlm.nih.gov/18425900/
  • Reveiz L, Rueda J-R, Cardona AF. Palliative endobronchial brachythera-py for non-small cell lung cancer. Cochrane Database Syst Rev [Internet]. 2012 Dec 12; 12. Disponible en: https://pub-med.ncbi.nlm.nih.gov/23235606/
  • NCCN Clinical Practice Guidelines in Oncology 2018. Non-Small Cell Lung. Disponible en: https://www.nccn.org/patients/guidelines/cancers.aspx#nsclc
  • Ahluwalia M, Baehring J, Brem H, Brem S, Butowski N, Campian JL, et al. Continue NCCN Guidelines Panel Disclosures NCCN Guidelines Version 3.2020 Central Nervous System Cancers. 2020.
  • Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet [Internet]. 2016 Oct 22;388(10055):2004-14. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27604504/
  • Weiner JP. Neurocognitive outcomes for patients with brain metastasis in the modern era: Benefit of treatment with hippocampal avoidance whole-brain radiotherapy plus memantine. J Clin Oncol [Internet]; 2020 38:1003-5. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32058847/
  • Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar LE, et al. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol [Internet]. 2012 Jul Sep 2020];2(3):210-25. Disponible en: /pmc/articles/PMC3808749/ ?report=abstract
  • Fuentes R, Osorio D, Expósito Hernandez J, Simancas-Racines D, Mar-tinez-Zapata MJ, Bonfill Cosp X. Surgery versus stereotactic radiothera-py for people with single or solitary brain metastasis. Cochrane Database Syst Rev. 2018 Aug 20;8(8):CD012086. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30125049/
  • Patil CG, Pricola K, Sarmiento JM, Garg SK, Bryant A, Black KL. Who-le brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases [Internet]. Vol. 2017, Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd; 2017. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28945270/
  • Lim SH, Lee JY, Lee MY, Kim HS, Lee J, Sun JM, et al. A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligometastases in non-small-cell lung cancer. Ann Oncol [Internet]. 2015 Apr 1;26(4):762-8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/25538174/
  • Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim D-W, et al. Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer. N Engl J Med [Internet]. 2017 Aug 31;377(9):829-38. Disponible en: http://www.nejm.org/doi/10.1056/NEJMoa1704795
  • Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer. N Engl J Med [Internet]. 2018 Jan 11; 378(2):11325. Disponible en: http://www.nejm.org/doi/10.1056/NEJMoa1713137
  • Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E. Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol [Internet]. 2013;24Suppl6:vi99-105. Disponible en: http://dx.doi.org/10.1093/annonc/mdt178
  • Dómine M, Moran T, Isla D, Martí JL, Sullivan I, Provencio M, et al. SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019). Clin Transl Oncol [Internet]. 2020 Feb 1;22(2):245-55. Disponible en: https://pub-med.ncbi.nlm.nih.gov/32040815/
  • Loo BW, Chair V, Bassetti M, Bauman J, Berman A, Blakely C, et al. Charles Florsheim patient advocate continue NCCN guidelines panel disclosures NCCN guidelines version 1.2021. Small Cell Lung Cancer. 2020.
  • Yang Y, Zhang D, Zhou X, Bao W, Ji Y, Sheng L, et al. Prophylactic cranial irradiation in resected small cell lung cancer: A systematic review with meta-analysis. J Cancer [Internet]. 2018;9(2):433-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29344290/
  • De Ruysscher D, Lueza B, Le Péchoux C, Johnson DH, O’Brien M, Mu-rray N, et al. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: Usefulness of the individual patient data meta-analysis. Ann Oncol [Internet]; 2016; 27:1818-28. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27436850/
  • Ettinger DS, Wood DE, Chair V, Aggarwal C, Aisner DL, Aker-ley W, et al. NCCN Guidelines Panel Disclosures NCCN Guideli-nes Version 1.2020 Malignant Pleural Mesothelioma. 2019
  • Baas P, Fennell D, Kerr KM, van Schil PE, Haas RL, Peters S. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol [Internet]. 2015;26(July):v31-9. Disponible en: http://dx.doi.org/10.1093/annonc/mdv199
  • Ettinger DS, Wood DE, Chair V, Aggarwal C, Aisner DL, Akerley W, et al. NCCN Guidelines Version 1.2020 Thymomas and Thymic Carcinomas. 2019.
  • Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(July):v40-55.
  • Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg [Internet]. 2011 Jul;128(1):305-10. Disponible en: /pmc/articles/PMC3124652/?report=abstract
Fuente de los datos: Dialnet